Mitochondrial diseases differ in their genes and share a shortage of working oxidative phosphorylation. One proposed strategy is to clear the damaged organelles by turning mitophagy up, whatever the mutation. This preprint tests that idea with a drug screen, and the idea does not survive the energy measurement.
The screen covered 1,971 compounds already approved by the U.S. Food and Drug Administration. Reporters tracked two steps. The first was nuclear entry of TFEB, transcription factor EB, a regulator of lysosome and autophagy genes. The second was the appearance of mitolysosomes, the structures in which mitochondria are delivered to lysosomes. Of the library, 294 compounds moved TFEB into the nucleus. Nine of those also increased mitolysosomes without, by the authors' criteria, killing the cells or damaging mitochondria.
Two of the nine were taken forward in fibroblasts from patients. Meptazinol ranked first in cells with complex I deficiency. Ponatinib ranked first in cells with complex IV deficiency. Both raised mitophagy. Neither rescued the bioenergetic defect. The authors' conclusion is that stimulating mitophagy, on its own, was not sufficient to improve the oxidative phosphorylation defect in these cells.
Metal and redox
Complex I and complex IV are the names of the patient-cell defects. They are not, in this abstract, a reported iron-sulfur cluster, heme, or copper site. No drug is shown binding a metal. The redox fact that is present is negative: the energy-production defect remained after mitophagy increased.
What this does not show
A rank in a screen is not a clinical result. Meptazinol and ponatinib are not recommended here. The abstract does not give the exact genetic diagnosis, the dose, or the bioenergetic assay behind the failed rescue. This is a preprint read from the abstract. It is not medical advice.
